Yahui Peng1,2, Dinggang Shen3, Shu Liao3, Baris Turkbey4, Soroush Rais-Bahrami5, Bradford Wood5, Ibrahim Karademir2, Tatjana Antic6, Ambereen Yousef2, Yulei Jiang2, Peter A Pinto5, Peter L Choyke7, Aytekin Oto2. 1. School of Electronic and Information Engineering, Beijing Jiaotong University, Beijing, China. 2. Department of Radiology, University of Chicago, Chicago, Illinois, USA. 3. Department of Radiology, University of North Carolina, Chapel Hill, North Carolina, USA. 4. Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. 5. Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. 6. Department of Pathology, University of Chicago, Illinois, USA. 7. Diagnostic Radiology Department, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
PURPOSE: To determine whether prostate-specific antigen (PSA) levels adjusted by prostate and zonal volumes estimated from magnetic resonance imaging (MRI) improve the diagnosis of prostate cancer (PCa) and differentiation between patients who harbor high-Gleason-sum PCa and those without PCa. MATERIALS AND METHODS: This retrospective study was Health Insurance Portability and Accountability Act (HIPAA)-compliant and approved by the Institutional Review Board of participating medical institutions. T2 -weighted MR images were acquired for 61 PCa patients and 100 patients with elevated PSA but without PCa. Computer methods were used to segment prostate and zonal structures and to estimate the total prostate and central-gland (CG) volumes, which were then used to calculate CG volume fraction, PSA density, and PSA density adjusted by CG volume. These quantities were used to differentiate patients with and without PCa. Area under the receiver operating characteristic curve (AUC) was used as the figure of merit. RESULTS: The total prostate and CG volumes, CG volume fraction, and PSA density adjusted by the total prostate and CG volumes were statistically significantly different between patients with PCa and patients without PCa (P ≤ 0.007). AUC values for the total prostate and CG volumes, and PSA density adjusted by CG volume, were 0.68 ± 0.04, 0.68 ± 0.04, and 0.66 ± 0.04, respectively, and were significantly better than that of PSA (P < 0.02), for differentiation of PCa patients from patients without PCa. CONCLUSION: The total prostate and CG volumes estimated from T2 -weighted MR images and PSA density adjusted by these volumes can improve the effectiveness of PSA for the diagnosis of PCa and differentiation of high-Gleason-sum PCa patients from patients without PCa.
PURPOSE: To determine whether prostate-specific antigen (PSA) levels adjusted by prostate and zonal volumes estimated from magnetic resonance imaging (MRI) improve the diagnosis of prostate cancer (PCa) and differentiation between patients who harbor high-Gleason-sum PCa and those without PCa. MATERIALS AND METHODS: This retrospective study was Health Insurance Portability and Accountability Act (HIPAA)-compliant and approved by the Institutional Review Board of participating medical institutions. T2 -weighted MR images were acquired for 61 PCa patients and 100 patients with elevated PSA but without PCa. Computer methods were used to segment prostate and zonal structures and to estimate the total prostate and central-gland (CG) volumes, which were then used to calculate CG volume fraction, PSA density, and PSA density adjusted by CG volume. These quantities were used to differentiate patients with and without PCa. Area under the receiver operating characteristic curve (AUC) was used as the figure of merit. RESULTS: The total prostate and CG volumes, CG volume fraction, and PSA density adjusted by the total prostate and CG volumes were statistically significantly different between patients with PCa and patients without PCa (P ≤ 0.007). AUC values for the total prostate and CG volumes, and PSA density adjusted by CG volume, were 0.68 ± 0.04, 0.68 ± 0.04, and 0.66 ± 0.04, respectively, and were significantly better than that of PSA (P < 0.02), for differentiation of PCa patients from patients without PCa. CONCLUSION: The total prostate and CG volumes estimated from T2 -weighted MR images and PSA density adjusted by these volumes can improve the effectiveness of PSA for the diagnosis of PCa and differentiation of high-Gleason-sum PCa patients from patients without PCa.
Authors: Findlay MacAskill; Su-Min Lee; David Eldred-Evans; Wahyu Wulaningsih; Rick Popert; Konrad Wolfe; Mieke Van Hemelrijck; Giles Rottenberg; Sidath H Liyanage; Peter Acher Journal: Int Urol Nephrol Date: 2017-05-05 Impact factor: 2.370
Authors: Mirabela Rusu; Andrei S Purysko; Sadhna Verma; Jonathan Kiechle; Jay Gollamudi; Soumya Ghose; Karin Herrmann; Vikas Gulani; Raj Paspulati; Lee Ponsky; Maret Böhm; Anne-Maree Haynes; Daniel Moses; Ron Shnier; Warick Delprado; James Thompson; Phillip Stricker; Anant Madabhushi Journal: Sci Rep Date: 2017-02-01 Impact factor: 4.379
Authors: Katherine G Holder; Bernardo Galvan; Andrew S Knight; Freedom Ha; Reagan Collins; Preston E Weaver; Luis Brandi; Werner T de Riese Journal: Investig Clin Urol Date: 2021-05-31